Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Georgia: - Northside Hospital-Alpharetta — Alpharetta, Georgia
- Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Piedmont Hospital — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Georgia: - Phoebe Putney Memorial Hospital — Albany, Georgia
- Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Sites in Georgia: - Emory University Winship Cancer Institute — Atlanta, Georgia
- Lewis Cancer and Research Pavilion — Savannah, Georgia
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Georgia: - Research Site — Atlanta, Georgia
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in Georgia: - Northwest Georgia Oncology Centers PC - Marietta — Marietta, Georgia
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Georgia: - City of Hope - Cancer Center Atlanta — Newnan, Georgia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Georgia: - Local Institution - 0294 — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in Georgia: - Clinical Trial Site — Marietta, Georgia
Phase 3 Recruiting Industry
The Nanosomal Docetaxel Lipid Suspension (NDLS) consists of uniformly sized micro particles of docetaxel suspended in a lipid based formulation. The advantage of such a Lipid Based formulation of Docetaxel is an improvement of the safety p…
Sponsor: Jina Pharmaceuticals Inc.
NCT ID: NCT03671044
Sites in Georgia: - Columbus Regional Research Institute, LLC — Columbus, Georgia
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Georgia: - CTCA at Southeastern Regional Medical Center — Newnan, Georgia
Phase 1, Phase 2 Recruiting Industry
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced…
Sponsor: Pfizer
NCT ID: NCT06966453
Sites in Georgia: - Winship Cancer Institute @ Emory University Hospital Midtown — Atlanta, Georgia
- Emory Clinic Investigational Drug Services — Atlanta, Georgia
- Emory University Hospital — Atlanta, Georgia
- Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Georgia: - Augusta University Georgia Cancer Center — Augusta, Georgia
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in Georgia: - Winship Cancer Institute, Emory University — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Georgia: - Winship Cancer Institute — Atlanta, Georgia
- Georgia Cancer Center — Augusta, Georgia
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic…
Sponsor: Genentech, Inc.
NCT ID: NCT07100106
Sites in Georgia: - Winship Cancer Institute of Emory University — Atlanta, Georgia
Phase 2 Recruiting Industry
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESA…
Sponsor: GlaxoSmithKline
NCT ID: NCT04641247
Sites in Georgia: - GSK Investigational Site — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibi…
Sponsor: Medicenna Therapeutics, Inc.
NCT ID: NCT05086692
Sites in Georgia: - Emory - Winship Cancer Institute — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Sponsor: Kathy Miller
NCT ID: NCT05846789
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Sponsor: Yale University
NCT ID: NCT06750484
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …
Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Georgia: - Emory University School of Medicine - Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the safety and t…
Sponsor: SillaJen, Inc.
NCT ID: NCT05768932
Sites in Georgia: - Winship Cancer Institute / Emory University — Atlanta, Georgia
Phase 1 Recruiting Industry
The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH).
Sponsor: TerSera Therapeutics LLC
NCT ID: NCT07310420
Sites in Georgia: - Summit Cancer Care — Savannah, Georgia
Phase 1 Recruiting Industry
This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Sponsor: Compass Therapeutics
NCT ID: NCT06150664
Sites in Georgia: - University Cancer & Blood Center — Athens, Georgia